Reissig A, Kroegel C
Pneumologie und Allergologie, Klinik Innere Medizin I, Friedrich-Schiller-Universität Jena.
Internist (Berl). 2004 May;45(5):540-8. doi: 10.1007/s00108-004-1168-9.
The diagnosis of pulmonary embolism (PE) remains a considerable challenge to any physician. Irrespective of the diagnostic progress, the prevalence of fatal PE in autopsy studies is still about one third. Introducing sufficient anticoagulant therapy, mortality due to PE can be decreased from about 30% to 2-8%. Therefore, immediate anticoagulant therapy should be given, if PE is clinically suspected. Initial anticoagulation by low-molecular-weight heparins is as effective as unfractionated heparin in non-massive PE. In patients suffering from massive PE, thrombolytic treatment is indicated. Whether patients with submassive PE and/or elevated cardial troponins should also receive thrombolytic treatment, is still under debate. After PE has been established, vitamin-k-antagonists are the current standard of secondary prophylaxis.
肺栓塞(PE)的诊断对任何医生来说仍然是一项重大挑战。无论诊断技术如何进步,尸检研究中致命性肺栓塞的发生率仍约为三分之一。采用充分的抗凝治疗,肺栓塞导致的死亡率可从约30%降至2%-8%。因此,如果临床上怀疑肺栓塞,应立即给予抗凝治疗。在非大面积肺栓塞中,低分子量肝素进行初始抗凝治疗与普通肝素一样有效。对于大面积肺栓塞患者,应进行溶栓治疗。亚大面积肺栓塞和/或心肌肌钙蛋白升高的患者是否也应接受溶栓治疗仍存在争议。在确诊肺栓塞后,维生素K拮抗剂是目前二级预防的标准治疗方法。